eptinezumab
Generic: ALD403·Brand: Vyepti·Code: ALD403
eptinezumab: developed by 1 company · 2 clinical trials tracked.
eptinezumab evidence translation
What we can confirm
2 tracked trials
What it means
Source-backed records connect eptinezumab to ALDR; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could eptinezumab → ALDR affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| ALDER BIOPHARMACEUTICALS INC (ALDR) prevention of migraine | BLA Filed |
Clinical Trials (2)
Migraine Medication Effects on Urinary Symptoms
Primary endpoint: changes in OAB symptoms
Observational200 targetStarted 2024-04Completion 2026-121 site · United StatesThe Cleveland Clinic
China HeadAche DIsorders RegiStry
Primary endpoint: Headache Days
Observational10,000 targetStarted 2022-08Completion 2032-1250 sites · ChinaBeijing Tiantan Hospital
Frequently asked questions
Who is developing eptinezumab?
eptinezumab is being developed by ALDER BIOPHARMACEUTICALS INC.
How many clinical trials involve eptinezumab?
BioSniper tracks 2 clinical trials involving eptinezumab.